Abstract
Current therapies controlling inflammation in patients with Crohn’s disease do not modify natural disease progression to stenosis, suggesting that the molecular mechanisms contributing to intestinal fibrosis occur partly independent from inflammation. This may be explained by auto-propagation of fibrosis, accomplished by components of the interstitial, non-cellular environment referred to as the extracellular matrix (ECM). Aside from its function in maintaining tissue integrity, the ECM is a highly dynamic structure that closely communicates with cells, including with those that produce ECM components. Interaction of fibroblasts with the ECM through multi-protein focal adhesions orchestrates a variety of processes including proliferation, migration and activation. In particular, the mechanical properties of the ECM, determined by the degree of ‘stiffness’ which is typically increased in the stenotic bowel, induces a variety of pro-fibrotic signaling cascades in fibroblasts. Although the mechanical cues translating into the activation of these cells have only begun to be unraveled, mechanotransduction in fibroblasts should be considered as an important inflammation-independent contributor to intestinal fibrosis. In addition, the ECM is a reservoir of growth factors and a source of ‘danger signals’ that can trigger pro-fibrotic responses in the rigid ECM. This chapter provides an overview of the components of the intestinal ECM, the interaction with fibroblasts, and the inflammation-independent mechanisms contributing to fibrosis including mechanotransduction of fibroblasts and mechanical activation of the ECM. Finally, the potential therapeutic targets in these pathways to tackle fibrogenesis in the intestine are discussed.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Gayer CP, Basson MD. The effects of mechanical forces on intestinal physiology and pathology. Cell Signal. 2009;21(8):1237–44.
Bosman FT, Stamenkovic I. Functional structure and composition of the extracellular matrix. J Pathol. 2003;200(4):423–8.
Bateman JF, Boot-Handford RP, Lamande SR. Genetic diseases of connective tissues: cellular and extracellular effects of ECM mutations. Nat Rev Genet. 2009;10(3):173–83.
Rozario T, DeSimone DW. The extracellular matrix in development and morphogenesis: a dynamic view. Dev Biol. 2010;341(1):126–40.
Shimshoni E, et al. ECM remodelling in IBD: innocent bystander or partner in crime? The emerging role of extracellular molecular events in sustaining intestinal inflammation. Gut. 2015;64(3):367–72.
Kedinger M, et al. Intestinal epithelial-mesenchymal cell interactions. Ann N Y Acad Sci. 1998;859:1–17.
Naba A, et al. The matrisome: in silico definition and in vivo characterization by proteomics of normal and tumor extracellular matrices. Mol Cell Proteomics. 2012;11(4):M111.014647.
Ricard-Blum S. The collagen family. Cold Spring Harb Perspect Biol. 2011;3(1):a004978.
Mouw JK, Ou G, Weaver VM. Extracellular matrix assembly: a multiscale deconstruction. Nat Rev Mol Cell Biol. 2014;15(12):771–85.
Graham MF, et al. Collagen content and types in the intestinal strictures of Crohn’s disease. Gastroenterology. 1988;94(2):257–65.
Shelley-Fraser G, et al. The connective tissue changes of Crohn’s disease. Histopathology. 2012;60(7):1034–44.
Johnson LA, et al. Matrix stiffness corresponding to strictured bowel induces a fibrogenic response in human colonic fibroblasts. Inflamm Bowel Dis. 2013;19(5):891–903.
Esko JD, Kimata K, Lindahl U. Proteoglycans and sulfated glycosaminoglycans. In: Varki A, et al., editors. Essentials of glycobiology. New York: Cold Spring Harbor; 2009.
Jarvinen TA, Prince S. Decorin: a growth factor antagonist for tumor growth inhibition. Biomed Res Int. 2015;2015:654765.
Couchman JR. Transmembrane signaling proteoglycans. Annu Rev Cell Dev Biol. 2010;26:89–114.
Herum KM, et al. The soft- and hard-heartedness of cardiac fibroblasts: mechanotransduction signaling pathways in fibrosis of the heart. J Clin Med. 2017;6(5):E53.
Hynes WL, Walton SL. Hyaluronidases of Gram-positive bacteria. FEMS Microbiol Lett. 2000;183(2):201–7.
Spiro RG. Glycoproteins: structure, metabolism and biology. N Engl J Med. 1963;269:616–21.
Bouatrouss Y, et al. Altered expression of laminins in Crohn’s disease small intestinal mucosa. Am J Pathol. 2000;156(1):45–50.
Serini G, et al. The fibronectin domain ED-A is crucial for myofibroblastic phenotype induction by transforming growth factor-beta1. J Cell Biol. 1998;142(3):873–81.
Brenmoehl J, et al. Evidence for a differential expression of fibronectin splice forms ED-A and ED-B in Crohn’s disease (CD) mucosa. Int J Colorectal Dis. 2007;22(6):611–23.
Zemskov EA, et al. The role of tissue transglutaminase in cell-matrix interactions. Front Biosci. 2006;11:1057–76.
Morgan MR, Humphries MJ, Bass MD. Synergistic control of cell adhesion by integrins and syndecans. Nat Rev Mol Cell Biol. 2007;8(12):957–69.
Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell. 2002;110(6):673–87.
Zaidel-Bar R, et al. Functional atlas of the integrin adhesome. Nat Cell Biol. 2007;9(8):858–67.
Schiller HB, et al. Beta1- and alphav-class integrins cooperate to regulate myosin II during rigidity sensing of fibronectin-based microenvironments. Nat Cell Biol. 2013;15(6):625–36.
Ierardi E, et al. Altered molecular pattern of mucosal healing in Crohn’s disease fibrotic stenosis. World J Gastrointest Pathophysiol. 2013;4(3):53–8.
Floer M, et al. Enoxaparin improves the course of dextran sodium sulfate-induced colitis in syndecan-1-deficient mice. Am J Pathol. 2010;176(1):146–57.
Akimov SS, et al. Tissue transglutaminase is an integrin-binding adhesion coreceptor for fibronectin. J Cell Biol. 2000;148(4):825–38.
Hinz B. The myofibroblast: paradigm for a mechanically active cell. J Biomech. 2010;43(1):146–55.
Gabbiani G, Ryan GB, Majne G. Presence of modified fibroblasts in granulation tissue and their possible role in wound contraction. Experientia. 1971;27(5):549–50.
Tomasek JJ, et al. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol. 2002;3(5):349–63.
Hinz B, et al. Mechanical tension controls granulation tissue contractile activity and myofibroblast differentiation. Am J Pathol. 2001;159(3):1009–20.
Parker MW, et al. Fibrotic extracellular matrix activates a profibrotic positive feedback loop. J Clin Invest. 2014;124(4):1622–35.
Georges PC, et al. Increased stiffness of the rat liver precedes matrix deposition: implications for fibrosis. Am J Physiol Gastrointest Liver Physiol. 2007;293(6):G1147–54.
Stephens P, et al. Crosslinking and G-protein functions of transglutaminase 2 contribute differentially to fibroblast wound healing responses. J Cell Sci. 2004;117(Pt 15):3389–403.
van der Slot AJ, et al. Elevated formation of pyridinoline cross-links by profibrotic cytokines is associated with enhanced lysyl hydroxylase 2b levels. Biochim Biophys Acta. 2005;1741(1-2):95–102.
Yang J, et al. Targeting LOXL2 for cardiac interstitial fibrosis and heart failure treatment. Nat Commun. 2016;7:13710.
Rivera E, et al. Molecular profiling of a rat model of colitis: validation of known inflammatory genes and identification of novel disease-associated targets. Inflamm Bowel Dis. 2006;12(10):950–66.
Mambetsariev I, et al. Stiffness-activated GEF-H1 expression exacerbates LPS-induced lung inflammation. PLoS One. 2014;9(4):e92670.
Kim K, et al. Noninvasive ultrasound elasticity imaging (UEI) of Crohn’s disease: animal model. Ultrasound Med Biol. 2008;34(6):902–12.
Stidham RW, et al. Ultrasound elasticity imaging for detecting intestinal fibrosis and inflammation in rats and humans with Crohn’s disease. Gastroenterology. 2011;141(3):819–826 e1.
Rault I, et al. Evaluation of different chemical methods for cross-linking collagen gel, films and sponges. J Mater Sci Mater Med. 1996;7(4):215–21.
Syedain ZH, et al. Controlled compaction with ruthenium-catalyzed photochemical cross-linking of fibrin-based engineered connective tissue. Biomaterials. 2009;30(35):6695–701.
Badylak SF, et al. The use of xenogeneic small intestinal submucosa as a biomaterial for Achilles tendon repair in a dog model. J Biomed Mater Res. 1995;29(8):977–85.
Lo CM, et al. Cell movement is guided by the rigidity of the substrate. Biophys J. 2000;79(1):144–52.
Goffin JM, et al. Focal adhesion size controls tension-dependent recruitment of alpha-smooth muscle actin to stress fibers. J Cell Biol. 2006;172(2):259–68.
Trappmann B, Chen CS. How cells sense extracellular matrix stiffness: a material’s perspective. Curr Opin Biotechnol. 2013;24(5):948–53.
Bershadsky A, Kozlov M, Geiger B. Adhesion-mediated mechanosensitivity: a time to experiment, and a time to theorize. Curr Opin Cell Biol. 2006;18(5):472–81.
Discher DE, Janmey P, Wang YL. Tissue cells feel and respond to the stiffness of their substrate. Science. 2005;310(5751):1139–43.
Wang N, et al. Cell prestress. I. Stiffness and prestress are closely associated in adherent contractile cells. Am J Physiol Cell Physiol. 2002;282(3):C606–16.
Hinz B, et al. Alpha-smooth muscle actin expression upregulates fibroblast contractile activity. Mol Biol Cell. 2001;12(9):2730–41.
Sullivan KM, et al. A model of scarless human fetal wound repair is deficient in transforming growth factor beta. J Pediatr Surg. 1995;30(2):198–202; discussion 202-3.
Kim SJ, et al. Autoinduction of transforming growth factor beta 1 is mediated by the AP-1 complex. Mol Cell Biol. 1990;10(4):1492–7.
Xia H, et al. Focal adhesion kinase is upstream of phosphatidylinositol 3-kinase/Akt in regulating fibroblast survival in response to contraction of type I collagen matrices via a beta 1 integrin viability signaling pathway. J Biol Chem. 2004;279(31):33024–34.
Zhang HY, Phan SH. Inhibition of myofibroblast apoptosis by transforming growth factor beta(1). Am J Respir Cell Mol Biol. 1999;21(6):658–65.
Holvoet T, et al. Treatment of intestinal fibrosis in experimental inflammatory bowel disease by the pleiotropic actions of a local Rho kinase inhibitor. Gastroenterology. 2017;153(4):1054–67.
Miyazono K, Ichijo H, Heldin CH. Transforming growth factor-beta: latent forms, binding proteins and receptors. Growth Factors. 1993;8(1):11–22.
Henderson NC, et al. Targeting of alphav integrin identifies a core molecular pathway that regulates fibrosis in several organs. Nat Med. 2013;19(12):1617–24.
Khalil N. TGF-beta: from latent to active. Microbes Infect. 1999;1(15):1255–63.
Wipff PJ, et al. Myofibroblast contraction activates latent TGF-beta1 from the extracellular matrix. J Cell Biol. 2007;179(6):1311–23.
Verrecchia F, Chu ML, Mauviel A. Identification of novel TGF-beta/Smad gene targets in dermal fibroblasts using a combined cDNA microarray/promoter transactivation approach. J Biol Chem. 2001;276(20):17058–62.
Maeda T, et al. Conversion of mechanical force into TGF-beta-mediated biochemical signals. Curr Biol. 2011;21(11):933–41.
Grafe I, et al. Excessive transforming growth factor-beta signaling is a common mechanism in osteogenesis imperfecta. Nat Med. 2014;20(6):670–5.
Otte JM, Rosenberg IM, Podolsky DK. Intestinal myofibroblasts in innate immune responses of the intestine. Gastroenterology. 2003;124(7):1866–78.
Scheibner KA, et al. Hyaluronan fragments act as an endogenous danger signal by engaging TLR2. J Immunol. 2006;177(2):1272–81.
Soroosh A, et al. Crohn’s disease fibroblasts overproduce the novel protein KIAA1199 to create proinflammatory hyaluronan fragments. Cell Mol Gastroenterol Hepatol. 2016;2(3):358–368 e4.
Kessler S, et al. Hyaluronan (HA) deposition precedes and promotes leukocyte recruitment in intestinal inflammation. Clin Transl Sci. 2008;1(1):57–61.
Kelsh R, et al. Regulation of the innate immune response by fibronectin: synergism between the III-1 and EDA domains. PLoS One. 2014;9(7):e102974.
Cosnes J, et al. Impact of the increasing use of immunosuppressants in Crohn’s disease on the need for intestinal surgery. Gut. 2005;54(2):237–41.
Louis E, et al. Behaviour of Crohn’s disease according to the Vienna classification: changing pattern over the course of the disease. Gut. 2001;49(6):777–82.
Johnson LA, et al. Intestinal fibrosis is reduced by early elimination of inflammation in a mouse model of IBD: impact of a “Top-Down” approach to intestinal fibrosis in mice. Inflamm Bowel Dis. 2012;18(3):460–71.
Seif-Naraghi SB, et al. Safety and efficacy of an injectable extracellular matrix hydrogel for treating myocardial infarction. Sci Transl Med. 2013;5(173):173ra25.
Enemchukwu NO, et al. Synthetic matrices reveal contributions of ECM biophysical and biochemical properties to epithelial morphogenesis. J Cell Biol. 2016;212(1):113–24.
Wassenaar JW, et al. Evidence for mechanisms underlying the functional benefits of a myocardial matrix hydrogel for post-MI treatment. J Am Coll Cardiol. 2016;67(9):1074–86.
Yoshizumi T, et al. Timing effect of intramyocardial hydrogel injection for positively impacting left ventricular remodeling after myocardial infarction. Biomaterials. 2016;83:182–93.
Barry-Hamilton V, et al. Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment. Nat Med. 2010;16(9):1009–17.
Johnson TS, et al. Transglutaminase inhibition reduces fibrosis and preserves function in experimental chronic kidney disease. J Am Soc Nephrol. 2007;18(12):3078–88.
Holzer LA, Holzer G. Injectable collagenase clostridium histolyticum for Dupuytren’s contracture. N Engl J Med. 2009;361(26):2579; author reply 2579-80.
McKleroy W, Lee TH, Atabai K. Always cleave up your mess: targeting collagen degradation to treat tissue fibrosis. Am J Physiol Lung Cell Mol Physiol. 2013;304(11):L709–21.
Hill LJ, Ahmed Z, Logan A. Decorin treatment for reversing trabecular meshwork fibrosis in open-angle glaucoma. Neural Regen Res. 2016;11(6):922–3.
Diebold RJ, et al. Early-onset multifocal inflammation in the transforming growth factor beta 1-null mouse is lymphocyte mediated. Proc Natl Acad Sci U S A. 1995;92(26):12215–9.
Monteleone G, et al. Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn’s disease. N Engl J Med. 2015;372(12):1104–13.
Patsenker E, et al. Pharmacological inhibition of integrin alphavbeta3 aggravates experimental liver fibrosis and suppresses hepatic angiogenesis. Hepatology. 2009;50(5):1501–11.
Lo DJ, et al. Inhibition of alphavbeta6 promotes acute renal allograft rejection in nonhuman primates. Am J Transplant. 2013;13(12):3085–93.
Targan SR, et al. Natalizumab for the treatment of active Crohn’s disease: results of the ENCORE Trial. Gastroenterology. 2007;132(5):1672–83.
Johnson LA, et al. Novel Rho/MRTF/SRF inhibitors block matrix-stiffness and TGF-beta-induced fibrogenesis in human colonic myofibroblasts. Inflamm Bowel Dis. 2014;20(1):154–65.
Fan GP, et al. Pharmacological inhibition of focal adhesion kinase attenuates cardiac fibrosis in mice cardiac fibroblast and post-myocardial-infarction models. Cell Physiol Biochem. 2015;37(2):515–26.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Laukens, D. (2018). Inflammation-Independent Mechanisms of Intestinal Fibrosis: The Role of the Extracellular Matrix. In: Rieder, F. (eds) Fibrostenotic Inflammatory Bowel Disease. Springer, Cham. https://doi.org/10.1007/978-3-319-90578-5_6
Download citation
DOI: https://doi.org/10.1007/978-3-319-90578-5_6
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-90577-8
Online ISBN: 978-3-319-90578-5
eBook Packages: MedicineMedicine (R0)